Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.3 (
ATPase
)
65,361
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Beryllium fluoride
(BeFx) has been widely used as a phosphate analogue in nucleotide-binding proteins. It was found to bind tightly to F- but not G-actin (Combeau C., and Carlier M. F. (1988) J. Biol. Chem. 263, 17429-17436) and to affect the three-dimensional structure of filaments by stabilizing the subdomain 2 region of the actin promoter (Orlova, A., and Egelman, E. H. (1992) J. Mol. Biol. 227, 1043-1053). In this work we examined the BeFx-induced structural and functional changes in G- and F-actin by using proteolysis, chemical modifications,
ATPase
, and in vitro motility assays. The results of proteolysis studies show that BeFx binds also to MgADP-G-actin and renders its subdomain 2 region more similar to that in MgATP-G-actin. This is manifested in enhanced subtilisin and decreased tryptic digestions in subdomain 2 of G-actin. BeFx had a strong effect on the proteolysis of MgADP-F-actin: both the tryptic and subtilisin digestions in subdomain 2 were completely inhibited. Significant protection against proteolysis in this region was observed even at 1:14 molar ratios of BeFx to actin indicating cooperative effects on the structure of the actin filament. A similar although milder effect of phosphate on the proteolysis of F-actin suggests that BeFx acts as a phosphate analogue in this system. BeFx also induces changes in the subdomain 1 region of F-actin. This is revealed via reduced rates of Cys-374 alkylation with 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin and an increased subtilisin cleavage near the C terminus of actin in the presence of BeFx. The BeFx-induced structural changes in actin have little effect on its interactions with myosin. BeFx inhibits only slightly the actin-activated
ATPase
activity of S1 by decreasing Vmax without affecting KM. Additionally, the binding of BeFx to actin does not change the sliding velocity of actin filaments in the in vitro motility assays. The BeFx-induced specific and distinct changes in G- and F-actin point to the dynamic nature of actin structure and the local differences between monomeric and polymeric forms of actin.
...
PMID:Dynamic properties of actin. Structural changes induced by beryllium fluoride. 816 84
Fluoroaluminate and fluoroberyllate are potent inhibitors of the
ATPase
activity of myosin. Inhibition requires the presence of ADP, and much evidence has accumulated to suggest that the tetrahedral fluoroaluminate and fluoroberyllate ions act as phosphate analogues, binding with high affinity at the active site in the position normally occupied by the terminal phosphate of ATP. Both the S1-ADP-fluoroaluminate and the S1-ADP-fluoroberyllate species are thought to resemble kinetic intermediates in the actomyosin
ATPase
cycle. Characterization of S1-bound fluoroaluminate by 19F NMR is straightforward; a single resonance identified as AlF4- is observed easily [Maruta, S., Henry, G.D., Sykes, B.D., & Ikebe, M (1993) J. Biol. Chem. 268, 7093-7100]. Bound fluoroberyllate, by contrast, was found to give rise to four separate peaks: a downfield pair at -80 and -83.5 ppm and an upfield pair at -101.5 and -103 ppm, suggesting the existence of four distinct types of S1-ADP-fluoroberyllate complex. The relative intensities of the bound resonances can be altered by changing rhe F:Be ratio during complex formation. Integration of a spectrum acquired in the presence of a fluorine-labeled nucleotide derivative, 3'(2')-O-(4-fluorobenzoyl)-ADP, in place of ADP yielded a bound fluoride to nucleotide ratio of 1.7-1.9 to 1, showing that the major bound fluoroberyllate species cannot be BeF3- as is usually thought. It is proposed that the bound fluoroberyllates correspond to the neutral species
BeF2
(H2O)2 and BeFOH(H2O)2 and the negatively charged species [BeF2OH.H2O]- and [BeF3.H2O]-, although other possibilities are discussed.
...
PMID:Observation of multiple myosin subfragment 1-ADP-fluoroberyllate complexes by 19F NMR spectroscopy. 839 90
We have examined the energetics of the interactions of two kinesin constructs with nucleotide and microtubules to develop a structural model of kinesin-dependent motility. Dimerization of the constructs was found to reduce the maximum rate of the microtubule-activated kinesin
ATPase
5-fold.
Beryllium fluoride
and aluminum fluoride also reduce this rate, and they increase the affinity of kinesin for microtubules. By contrast, inorganic phosphate reduces the affinity of a dimeric kinesin construct for microtubules. These findings are consistent with a model in which the kinesin head can assume one of two conformations, "strong" or "weak" binding, determined by the nature of the nucleotide that occupies the active site. Data for dimeric kinesin are consistent with a model in which kinesin.ATP binds to the microtubule in a strong state with positive cooperativity; hydrolysis of ATP to ADP+P(i) leads to dissociation of one of the attached heads and converts the second, attached head to a weak state; and dissociation of phosphate allows the second head to reattach. These results also argue that a large free energy change is associated with formation of kinesin.ADP.P(i) and that this step is the major pathway for dissociation of kinesin from the microtubule.
...
PMID:Equilibrium studies of kinesin-nucleotide intermediates. 862 18
The ATP-sensitive potassium (K(ATP)) channel couples glucose metabolism to insulin secretion in pancreatic beta-cells. It comprises regulatory sulfonylurea receptor 1 and pore-forming Kir6.2 subunits. Binding and/or hydrolysis of Mg-nucleotides at the nucleotide-binding domains of sulfonylurea receptor 1 stimulates channel opening and leads to membrane hyperpolarization and inhibition of insulin secretion. We report here the first purification and functional characterization of sulfonylurea receptor 1. We also compared the
ATPase
activity of sulfonylurea receptor 1 with that of the isolated nucleotide-binding domains (fused to maltose-binding protein to improve solubility). Electron microscopy showed that nucleotide-binding domains purified as ring-like complexes corresponding to approximately 8 momomers. The
ATPase
activities expressed as maximal turnover rate [in nmol P(i).s(-1).(nmol protein)(-1)] were 0.03, 0.03, 0.13 and 0.08 for sulfonylurea receptor 1, nucleotide-binding domain 1, nucleotide-binding domain 2 and a mixture of nucleotide-binding domain 1 and nucleotide-binding domain 2, respectively. Corresponding K(m) values (in mm) were 0.1, 0.6, 0.65 and 0.56, respectively. Thus sulfonylurea receptor 1 has a lower K(m) than either of the isolated nucleotide-binding domains, and a lower maximal turnover rate than nucleotide-binding domain 2. Similar results were found with GTP, but the K(m) values were lower. Mutation of the Walker A lysine in nucleotide-binding domain 1 (K719A) or nucleotide-binding domain 2 (K1385M) inhibited the
ATPase
activity of sulfonylurea receptor 1 by 60% and 80%, respectively.
Beryllium fluoride
(K(i) 16 microm), but not MgADP, inhibited the
ATPase
activity of sulfonylurea receptor 1. In contrast, both MgADP and beryllium fluoride inhibited the
ATPase
activity of the nucleotide-binding domains. These data demonstrate that the
ATPase
activity of sulfonylurea receptor 1 differs from that of the isolated nucleotide-binding domains, suggesting that the transmembrane domains may influence the activity of the protein.
...
PMID:Studies of the ATPase activity of the ABC protein SUR1. 1756 60